, Tracking Stock Market Picks
Enter Symbol:
Array Biopharma Inc. (ARRY) [hlAlert]

down 43.24 %

Array Biopharma Inc. (ARRY) rated Buy with price target $16 by Collins Stewart

Posted on: Thursday,  Dec 20, 2007  10:25 AM ET by Collins Stewart

Collins Stewart rated Buy Array Biopharma Inc. (NASDAQ: ARRY) on 12/20/2007. Previously Collins Stewart rated Buy Array Biopharma Inc. (NASDAQ: ARRY) on
11/07/2007., when the stock price was $10.29. Since then, Array Biopharma Inc. has lost 43.25% as of 01/15/2016's recent price of $5.84.
If you would have followed the previous Collins Stewart's recommendation on ARRY, you would have lost 43.24% of your investment in 2991 days.

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The company's proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas.

Collins Stewart's research department is built around a number of sector-specialist teams. Our analysts are leaders in their area of specialisation and combine deep industry knowledge with decades of stock broking experience to produce insightful, independent sector research. Our research approach encompasses Questâ„¢ principles and focuses on cash-driven valuation techniques. Research is a Collins Stewart cornerstone; it is leveraged throughout the organisation.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/20/2007 10:25 AM Buy
7.90 16.00
as of 8/27/2015
1 Week up  2.09 %
1 Month down  -26.07 %
3 Months down  -18.88 %
1 YTD up  16.56 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/7/2007 9:25 AM Buy
10.29 17.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy